Acceleron Pharma Inc (NASDAQ:XLRN) Upgraded to “Strong-Buy” by BidaskClub
BidaskClub upgraded shares of Acceleron Pharma Inc (NASDAQ:XLRN) from a buy rating to a strong-buy rating in a report released on Sunday.
Other research analysts have also issued reports about the stock. FBR & Co reissued a buy rating on shares of Acceleron Pharma in a research note on Saturday, April 8th. CIBC lowered shares of Acceleron Pharma from an outperform rating to a market perform rating in a research note on Tuesday, June 13th. Morgan Stanley dropped their price objective on shares of Acceleron Pharma from $51.00 to $42.00 and set an overweight rating on the stock in a research note on Tuesday, June 13th. Oppenheimer Holdings, Inc. reaffirmed a market perform rating on shares of Acceleron Pharma in a research note on Tuesday, June 13th. Finally, Cann reaffirmed a hold rating on shares of Acceleron Pharma in a research note on Tuesday, June 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Acceleron Pharma currently has an average rating of Buy and a consensus target price of $41.53.
Shares of Acceleron Pharma (XLRN) traded down 0.50% during midday trading on Friday, hitting $35.51. 232,947 shares of the company were exchanged. The firm’s 50 day moving average price is $31.52 and its 200 day moving average price is $28.41. The firm’s market capitalization is $1.37 billion. Acceleron Pharma has a one year low of $23.07 and a one year high of $41.69.
Acceleron Pharma (NASDAQ:XLRN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by $0.12. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.69 million. Acceleron Pharma had a negative return on equity of 59.97% and a negative net margin of 970.53%. The firm’s revenue was down 3.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.59) earnings per share. Analysts forecast that Acceleron Pharma will post ($2.57) EPS for the current fiscal year.
WARNING: “Acceleron Pharma Inc (NASDAQ:XLRN) Upgraded to “Strong-Buy” by BidaskClub” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.dailypolitical.com/2017/08/07/acceleron-pharma-inc-nasdaqxlrn-upgraded-to-strong-buy-by-bidaskclub.html.
In other news, CFO Kevin F. Mclaughlin sold 34,400 shares of the stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $32.00, for a total value of $1,100,800.00. Following the completion of the sale, the chief financial officer now owns 80,950 shares in the company, valued at $2,590,400. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Matthew L. Sherman sold 16,000 shares of the stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $32.00, for a total transaction of $512,000.00. Following the completion of the sale, the executive vice president now owns 112,400 shares of the company’s stock, valued at approximately $3,596,800. The disclosure for this sale can be found here. In the last quarter, insiders sold 51,337 shares of company stock valued at $1,642,784. 3.90% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA increased its stake in shares of Acceleron Pharma by 969.9% in the second quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 3,288 shares in the last quarter. NJ State Employees Deferred Compensation Plan purchased a new stake in shares of Acceleron Pharma during the second quarter valued at approximately $213,000. Bank of Montreal Can purchased a new stake in shares of Acceleron Pharma during the first quarter valued at approximately $237,000. Parametric Portfolio Associates LLC purchased a new stake in shares of Acceleron Pharma during the first quarter valued at approximately $241,000. Finally, Tudor Investment Corp ET AL increased its stake in shares of Acceleron Pharma by 8.5% in the first quarter. Tudor Investment Corp ET AL now owns 9,105 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 716 shares in the last quarter. Institutional investors own 83.65% of the company’s stock.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.